Authors
Latest:
HR+/HER2- Metastatic Breast Cancer: Future Directions in CareClosing out their program on HR+/HER2- metastatic breast cancer, panelists look toward future evolutions in the treatment landscape.
Latest:
Adapting to Second-Line Restrictions of Niraparib in Ovarian CancerThe approved PARP inhibitor niraparib has been beneficial for patients with recurrent ovarian cancer, but new second-line restrictions for certain patients have led physicians to be more cautious when re-challenging these patients.
Latest:
Revolutionizing Lung Cancer Detection With Self-Taught AIAristotelis Tsirigos, PhD, discusses a self-taught artificial intelligence tool being developed to accurately diagnose cases of adenocarcinoma.
Latest:
Looking Towards the Future of Molecular Testing and Additional Treatment Options for Patients with mNSCLCThe panel closes by summarizing recent advances in the field and shares hopes for future improvements in molecular testing and treatment options for patients with mNSCLC.
Latest:
Advancing Myeloma Treatment With Blood-Based MRD TestingIn this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.
Latest:
JAK Inhibitors and Resistance in MyelofibrosisAnthony Hunter, MD, discusses JAK inhibitor resistance and optimal strategies for treatment of patients with myelofibrosis.
Latest:
c-Met as a Biomarker in Gastric/GEJ CancersJohn Strickler, MD, discusses targeting c-Met as a biomarker in gastric and gastroesophageal junction cancers.
Latest:
Updated Findings on Datopotamab Deruxtecan in Urothelial Cancer TreatmentFunda Meric-Bernstam, MD, discusses updated findings from the phase 1 TROPION-PanTumor01 study of datopotamab deruxtecan-dlnk in heavily pretreated locally advanced or metastatic urothelial cancer.
Latest:
NSCLC: Factors in Selecting 2L Therapy After Progression on 1L ALK TKIExpert perspectives on factors that aid in the selection of optimal therapy for patients with relapsed/refractory ALK+ non–small cell lung cancer.
Latest:
SHP2 Inhibitors Undergo Exploration in CombinationsMelissa Johnson, MD, discussed SHP2 inhibitors with Targeted Therapies in Oncology.
Latest:
ENDOLA Study Demonstrates Promise of Olaparib Triplet in Endometrial CancerAn olaparib triplet demonstrated efficacy in patients with recurrent advanced or metastatic endometrial cancer treated in the ENDOLA clinical trial.
Latest:
Considering Elacestrant in ESR1+ Breast Cancer After CDK4/6 InhibitionPaolo Tarantino, MD, PhD, discusses elacestrant as a treatment option for patients with ESR1-mutated metastatic breast cancer in the second line.
Latest:
Six Tips for Identifying Go-Getters for Your PracticeThe following list will provide you with suggestions for identifying the go-getters and how to include them in your practice or on your team.
Latest:
Ovarian Cancer Awareness Month: Strides in Up-front and Maintenance TherapyGizelka David-West, MD, analyzes the most compelling changes in up-front treatment and maintenance therapy for Ovarian Cancer Awareness Month.
Latest:
Utilizing MRD Testing in the Myeloma SpaceGayathri Ravi, MD, discusses the role minimal residual disease plays in decision making and treating patients with hematologic malignancies.
Latest:
Exploring Ongoing Trials With 177Lu-PSMA-617 in Prostate CancerArun Azad, MBBS, PhD, discusses ongoing studies of lutetium-177-PSMA radionuclide in patients with prostate cancer.
Latest:
HER2 Therapies Redefine Brain Metastasis Treatment in Breast CancerNovel HER2 therapies show strong intracranial efficacy, enabling systemic treatment over local therapy for small, asymptomatic brain metastases in metastatic breast cancer.
Latest:
Nirogacestat Shows Statistically Significant Improvements in Desmoid TumorsMrinal M. Gounder, MD, delves into the data supporting the recent FDA approval of nirogacestat for the treatment of adult patients with desmoid tumors.
Latest:
Relapsed/Refractory CLL: Practical Advice and Future Directions in CareA key opinion leader on relapsed/refractory chronic lymphocytic leukemia provides practical advice on patient management and looks toward future evolutions in the treatment landscape.
Latest:
Evaluating Tumor Lysis Syndrome in CLL/SLL Treated With VenetoclaxYannis K. Valtis, MD, provides background on a single-institution, retrospective cohort study which assessed laboratory and clinical tumor lysis syndrome in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Latest:
Remote Monitoring Improves Management of Symptoms in Patients With Lung Cancer After SurgeryBrett Simon, MD, PhD, discusses an ongoing program at his institution that aims to improve symptoms and outcomes for patients with lung cancer who have undergone surgery.
Latest:
Key Takeaways Regarding Biomarker Testing for mNSCLCClosing thoughts from a panel of NSCLC experts, with an emphasis on improving access to and utilization of biomarker testing for patients with the disease.
Latest:
OlympiA: Adj Olaparib Post (Neo) Adjuvant Chemo in Pts with Germline BRCA1/BRCA2 & High Risk HER2-negativePanelists discuss the OlympiA trial, evaluating adjuvant olaparib post-neoadjuvant chemotherapy in patients with germline BRCA1/BRCA2 mutations and high-risk HER2-negative breast cancer, and its impact on treatment outcomes.
Latest:
Future Directions and Unmet Needs in T-ALLBijal Shah, MD, MS, discusses the unmet medical needs in the T-cell acute lymphoblastic leukemia space and what future research aims to examine.
Latest:
PARP Inhibition in Metastatic CRPC: The PROfound and TRITON2 StudiesExpert perspectives on the PROfound and TRITON2 studies of olaparib and rucaparib, respectively, in metastatic castration-resistant prostate cancer.
